title: Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.
authors.forename: Scott A
authors.initials: SA
authors.lastname: Strassels
authors.forename: Michael
authors.initials: M
authors.lastname: Dickson
authors.forename: Leann B
authors.initials: LB
authors.lastname: Norris
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016527:Drug Costs; D005260:Female; D005334:Fever / Q000209:etiology*; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D009503:Neutropenia / Q000517:prevention & control*; D011092:Polyethylene Glycols; D011322:Primary Prevention / Q000191:economics*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim